Adverse cardiorenal effects of aldosterone: Is aldosterone antagonism beneficial?

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 3, 2005, Pages 497-512

  Coca, Steven G ^a   Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Cardiovascular disease; Congestive heart failure; Eplerenone hypertension; Kidney disease; Myocardial infarction; Proteinuria; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CILAZAPRIL; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; LOOP DIURETIC AGENT; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXPRENOATE POTASSIUM; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ACUTE KIDNEY FAILURE; ADD ON THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DISEASE COURSE; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GYNECOMASTIA; HEART MUSCLE FIBROSIS; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MAXIMUM PERMISSIBLE DOSE; MENSTRUAL IRREGULARITY; NONHUMAN; PATHOGENESIS; REVIEW;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES;

EID: 18844366445     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.3.497     Document Type: Review

References (103)

1. Takeda Y, Miyamori I, Inaba S et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 29, 45-48 (1997).
2. Gomez-Sanchez CE, Zhou MY, Cozza EN et al. Aldosterone biosynthesis in the rat brain. Endocrinology 138, 3369-3373 (1997).
3. Silvestre JS, Robert V, Heymes C et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. 273, 4883-4891 (1998).
4. Wehling M, Spes CH, Win N et al. Rapid cardiovascular action of aldosterone in man. J. Clin. Endocrinol. Metab. 83, 3517-3522 (1998).
5. Schmidt BMW, Montealegre A, Janson CP et al. Short-term cardiovascular effects of aldosterone in healthy male volunteers. J. Clin. Endocrinol. Metab. 84, 3528-3533 (1999).
6. Wehling M, Christ M, Theisen K. Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. Am. J. Physiol. 263, E974-E979 (1992).
7. Hansso L, Lindholm LH, Niskanen L et al. for the Captopril Prevention Project study group. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project randomised trial. Lancet 353, 611-616 (1999).
8. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 354, 1751-1756 (1999).
9. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
10. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362, 782-788 (2003).
11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316, 1429-1435 (1987).
12. The SOLVD Investigators.. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991).
13. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325, 303-310 (1991).
14. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial. Lancet 362, 772-776 (2003).
15. Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am. J. Hypertens. 9, 84S-92S (1994).
16. Jafar T, Schmid C, Landa M et al. Angiotensin-converting enzyme inhibitors and progression on nondiabetic renal disease. Ann. Intern. Med. 135, 73-87 (2001).
17. Brenner BM, Cooper ME, DeZeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
18. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
19. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 334, 939-945 (1996).
20. The GISEN Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 349, 857-863 (1997).
21. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J. Card. Fail. 2, 47-54 (1996).
22. Stassen J, Lijnen P, Fagard, R et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J. Endocrinol. 91, 457-465 (1981).
23. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOVLED) pilot study. The RESOLVED Pilot Study Investigators. Circulation 100, 1056-1064 (1999).
24. MacFadyen RJ, Lee AF, Morton JJ et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82, 57-61 (1999).
25. Jorde UP, Vittorio T, Katz SD et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 106, 1055-1057 (2002).
26. Pearlmann ES, Weber KT, Janicki JS, Pietra G, Fishman AP. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab. Invest. 46, 158-164 (1982).
27. Anderson KR, St John Sutton MG, Lie JT. Histopathological types of cardiac fibrosis in myocardial disease. J Pathol. 128, 79-85 (1979).
28. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ. Res. 67, 1355-1364 (1990).
29. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc. Res. 26, 671-677 (1992).
30. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am. J. Physiol. 269, E657-E662 (1995).
31. Brilla CG, Matsubara LS, Weber KT. Antialdosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J. Mol. Cell. Cardiol. 25, 563-575 (1993).
32. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am. J. Cardiol. 71, 12A-16A (1993).
33. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J. Lab. Clin. Med. 120, 893-901 (1992).
34. Sato A, Sartuta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens. Res. 27, 303-310 (2004).
35. Endemann DH, Touyz RM, Iglarz M et al. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43, 1252-1257 (2004).
36. Lal A, Veinot JP, Leenen FH. Prevention of high-salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. Am. J. Hypertens. 16, 319-323 (2003).
37. Takeda Y, Yoneda T, Demura M, Miayamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 36, 495-500 (2000).
38. Takeda Y, Yoneda T, Demura M, Miayamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 141, 1901-1904 (2000).
39. Darrow DC, Miller HC. The production of cardiac lesions by repeated injections of desoxycorticorticosterone acetate. J. Clin. Invest. 21, 601-611 (1942).
40. Campbell SE, Janicki JS, Matsubara BB, Weber KT. Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. Am. J. Hypertens. 6, 487-495 (1993).
41. Mirkovic S, Seymour AL, Fenning A et al. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br. J. Pharmacol. 135, 961-968 (2002).
42. Martinez DV, Rocha R, Matsumura M et al. Cardiac damage prevention by eplerenone: comparison with low-sodium diet or potassium loading. Hypertension 39, 614-618 (2002).
43. + pump activation during short-term exposure of cardiac myocytes to aldosterone. Am. J. Physiol. 274, C175-C181 (1998).
44. Weber KT. Aldosterone in congestive heart failure. N. Engl. J. Med. 345, 1689-1697 (2001).
45. Fiebeler A, Schmidt F, Muller DN et al. Mineralocorticoid receptor affects AP-1 and nuclear factor-κB activation in angiotensin II-induced cardiac injury. Hypertension 37(2), 787-793 (2001).
46. Robert V, Silverstre J-S, Charlemagne D et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 26, 971-978 (1995).
47. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283, H1802-H1810 (2002).
48. Rocha R, Martin-Berger CL, Pochang Y et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143, 4828-4836 (2002).
49. Fujisawa G, Dilley R, Fullerton MJ, Funder JW. Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration. Endocrinology 142, 3625-3631 (2001).
50. Brown NJ, Nakamura S, Ma L et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 58, 1219-1227 (2000).
51. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105, 2212-2216 (2002).
52. Ikeda U, Kanbe T, Nakayama I et al. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β. Eur. J. Pharmacol. 290, 69-73 (1995).
53. Garnier A, Bendall JK, Fuchs S et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110, 1819-1825 (2004).
54. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker in mild-to-moderate hypertension. Am. J. Hypertens. 15, 709-716 (2002).
55. Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40, 117-123 (2002).
56. Flack JM, Oparil S, Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. 41, 1148-1155 (2003).
57. Williams GH, Burgess E, Kollach RE et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am. J. Cardiol. 93, 990-996 (2004).
58. White WB, Duprez D, StHillaire R et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41, 1021-1026 (2003).
59. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311, 819-823 (1984).
60. Anand IS, Fisher LD, Chiang YT et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107(9), 1278-1283 (2003).
61. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch. Intern. Med. 153(8), 937-942 (1993).
62. Mizuno Y, Yoshimura M, Yasue H et al. Aldosterone production is activated in failing ventricle in humans. Circulation 103, 72-77 (2001).
63. Hollenberg NK. Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition. J. Am. Soc. Nephrol. 10, S239-S242 (1999).
64. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J. Int. Med. Res. 29, 13-21 (2001).
65. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102, 2700-2706, (2002).
66. Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101, 594-597 (2000).
67. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 90, 765-770 (2004).
68. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717 (1999).
69. Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658 (2001).
70. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309-1321 (2003).
71. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. Am. J. Cardiol. 78, 902-907 (1996).
72. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108, 1831-1838 (2003).
73. Mottram PM, Haluska B, Leano R et al. Effect of aldosterone anatagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110, 558-565 (2004).
74. Sato A, Hayashi M, Saruta T. Relative long-term effects of sprinolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens. Res. 25, 837-842 (2002).
75. Hayslett JP, Binder HJ. Mechanism of potassium adaptation. Am. J. Physiol. 243, F103-F112 (1982).
76. Rose LI, Underwood RH, Newmark SR, Kisch ES, Williams GH. Pathophysiology of spironolactone-induced gynecomastia. Ann. Intern. Med. 87, 398-403 (1977).
77. de Gasparo M, Joss U, Ramjoue S et al. Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther. 240, 650-656 (1987).
78. Karim A, Zagarella J, Jribar J, Dooley M, Spironolactone I. Disposition and metabolism. Clin. Pharmacol. Ther. 19, 158-169 (1976).
79. Sligl W, McAlister FA, Ezekowitz J, Armstrong PW. Usefulness of spironolactone in a specialized heart failure clinic. Am. J. Cardiol. 94, 443-447 (2004).
80. Meunemaitre X, Chatellier G, Kreft-Jais C et al. Efficacy and tolerance of spironolactone in essential hypertension. Am. J. Cardiol. 60, 820-825 (1987).
81. Reid JL, Whyte KF, Struthers AD. Epinephrine-induced hypokalemia: the role of β-adrenoreceptors. Am. J. Cardiol. 57, 23F-27F (1986).
82. Juurlink DN, Mamdani, MM, Lee DS et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N. Engl. J. Med. 351, 543-551 (2004).
83. Schepkens H, Vanholder R, Billiouw J-M, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am. J. Med. 110, 438-441 (2001).
84. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol. Dial. Transplant. 18, 1814-1819 (2003).
85. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atat D. How prevalent is hyperkalemia and renal dysfunction during treatment with spirolactone in patients with congestive heart failure? J. Card. Fail. 10, 297-303 (2004).
86. Tamirisa KP, Aaronson KD, Koelling TM. Sprionolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am. Heart J. 148, 971-978 (2004).
87. Perazella MA. COX-2 selective inhibitors: analysis of the renal effects. Expert Opin. Drug Saf. 1, 53-64 (2002).
88. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007 (1999).
89. Pfeffer MA, McMurray, JJ, Velazquez, EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349, 1893-1906 (2003).
90. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 38, 2101-2113 (2001).
91. Taylor CT. Eplerenone (Inspra) for hypertension. Am. Fam. Physician 69, 915-916 (2004).
92. Brewster EC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 116, 263-272 (2004).
93. Green EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98, 1063-1068 (1996).
94. Rocha R, Chander PN, Zucherman A, Stier CT. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33, 232-237 (1999).
95. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31, 451-458 (1998).
96. Rocha R, Chander PN, Zuckerman A, Stier CT. Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats. Hypertension 32, 598A (1998).
97. Rocha R, Stier CT, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141, 3871-3878 (2000).
98. Blasi ER, Rocha R, Rudolph AE et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63, 1791-1800 (2003).
99. Arima S, Kohagura K, Xu H-L et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J. Am. Soc. Nephrol. 14, 2255-2263 (2003).
100. Brenner B, Meyer T, Hostetter T. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med. 307, 652-659 (1982).
101. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41, 64-68 (2003).
102. Rachmani R, Slavachevsky I, Amit M et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet. Med. 21, 471-475 (2004).
103. Epstein M, Buckalew V, Martinez F et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. Am. J. Hypertens. 15, 24A (2002).